[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-369564-105":59,"doc-detail-369564-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","nutrient-gene-therapy-as-a-strategy-to-enhance-car-t-cell-function-and-overcome-barriers-in-the-tumor-microenvironment-review","Nutrient-gene therapy as a strategy to enhance CAR T cell function and overcome barriers in the tumor microenvironment - Review","","Cancer immunotherapy is transforming treatment for hematological and solid tumors. Despite early success of T-cell-based adoptive cell transfer (ACT), long-term efficacy is constrained by antigen specificity limitations, poor persistence and survival of transplanted T cells in vivo, and a hostile tumor microenvironment (TME). Existing CAR T-cell strategies have not fully solved durable retention and in vivo expansion within the TME. The review proposes nutrient gene therapy using GLUT1 overexpression to boost metabolic competency of adoptive CAR T cells, restrict tumor metabolites and ATP, disrupt the TME, reduce exhaustion, and improve durable antitumor function.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/nutrient-gene-therapy-as-a-strategy-to-enhance-car-t-cell-function-and-overcome-barriers-in-the-tumor-microenvironment-review/369564/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/nutrient-gene-therapy-as-a-strategy-to-enhance-car-t-cell-function-and-overcome-barriers-in-the-tumor-microenvironment-review/369564.png","ImageObject",300,407,{"name":92,"@type":93},"Sarah ","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-11","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What main barriers reduce the long-term efficacy of CAR T cell therapies?","Question",{"text":112,"@type":113},"Key obstacles include insufficient antigen specificity, limited survival and persistence of transplanted T cells in vivo, and an unfavorable tumor microenvironment (TME).","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What hypothesis does the review present to improve CAR T cell outcomes?",{"text":117,"@type":113},"It hypothesizes that enhancing donor T cells’ ability to compete with cancer cells for key nutrients can overcome T-cell exhaustion and sustain durable antitumor function in the TME.",{"name":119,"@type":110,"acceptedAnswer":120},"How does nutrient gene therapy using GLUT1 relate to the proposed treatment strategy?",{"text":121,"@type":113},"The approach uses genetic overexpression of GLUT1 (glucose transporter 1) to strengthen the metabolic competency of adoptive CAR T cells, deprive tumors of critical metabolites and ATP, and disrupt the TME.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},369564,1790216977,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},962085320529,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","Park et al. Journal of Translational Medicine (2025) 23:633  \n[https://doi.org/10.1186/s12967-025-06606-z](https://doi.org/10.1186/s12967-025-06606-z)  \nJournal of Translational Medicine  \n REVIEW Open Access  \nNutrient-gene therapy as a strategy  \nto enhance CART cell function and overcome barriers in the tumor microenvironment  \nBrandon Park1†, Joshua Kim1†, David J. Baylink 1, Christopher Hino1, Cedric Kwon1, Victoria Tran1, Jeffrey Xiao1, Huynh Cao2,3, Scott Lee4, Laren Tan5, Andrew Chang5, Luis Saca5, Michael Matus5, Pamela Lobo Moreno5, Amy Schill‑Depew5, Hisham Abdel‑Azim2,3, Hamid Mirshahidi2,3 and Yi Xu1,2,3*  \nAbstract  \nCancer immunotherapy is transforming the treatment landscape of both hematological and solid cancers. Although T‑cell‑based adoptive cell transfer (ACT) therapies have demonstrated initial success, several recurrent obstacles limit their long‑term anti‑tumor efficacy, including: (1) lack of antigen specificity; (2) poor long‑term survival of trans‑ planted T cells in vivo; and (3) a hostile tumor microenvironment (TME). While numerous approaches have been explored to enhance the antigen specificity of Chimeric Antigen Receptor (CAR) T‑cell therapies, the field still lacksan effective strategy to optimize the long‑term retention and in vivo expansion of engraftedT cells within the TME—a critical factor for the durable efficacy ofT‑cell‑based immunotherapies for both blood and solid cancers. Here, we hypothesize that the success of CART‑cell therapy can be enhanced by targeting donor T cells’ ability to compete with cancer cells for key nutrients, thereby overcoming T‑cell exhaustion and sustaining durable anti‑tumor func‑ tion in theTME. To explore this hypothesis, we first provide a comprehensively review of the current understanding of the metabolic interactions (e. g., glucose metabolism) between T cells and tumor cells. To address the challenges, we propose an innovative strategy: utilizing nutrient gene therapy (genetic overexpression of glucose transporter 1, GLUT1) to fortify the metabolic competency of adoptive CART‑cells, deprive tumors of critical metabolites and ATP, and disrupt the TME. Altogether, our proposed approach combining precision medicine (adoptive CART‑cell therapy) with tumor metabolism‑targeting strategies offers a promising and cost‑effective solution to enhance the efficacy and durability of ACT therapies, ultimately improving outcomes for cancer patients.  \nKeywords Cancer immunotherapy, Adoptive cell therapy, CART, TME, Metabolite, Nutrient, Glucose, GLUT1, Warburg effect, Gene therapy  \n†Brandon Park and Joshua Kim have contributed equally to this work.  \n*Correspondence: Yi Xu [dyxu@llu.edu](dyxu@llu.edu)  \n1 Division of Discovery, Innovation and Regenerative Medicine, Department of Medicine, School of Medicine, Loma Linda University, Loma Linda CA92354, USA.  \n2 Division of Hematology and Oncology, Department of Medicine, School of Medicine, Loma Linda University, Loma Linda CA92354, USA.  \n3 Loma Linda University Cancer Center, Loma Linda, CA 92354, USA.  \n4 Division of Endocrinology, Diabetes & Metabolism, Department of Medicine, School of Medicine, Loma Linda University, Loma Linda CA92354, USA.  \n5 Department of Medicine, School of Medicine, Loma Linda University, Loma Linda CA92354, USA.  \n© The Author(s) 2025. Open Access This article is licensed under a Creative Commons Attribution‑NonCommercial‑NoDerivatives 4.0 International License, which permits any non‑commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise ","cbCaii3iJsW5Yjqz","https://ap.wps.com/l/cbCaii3iJsW5Yjqz","pdf",4001846,18,"English","# Abstract\n## Background and rationale\n## Hypothesis and proposed strategy\n## Purpose and expected impact","[{\"question\":\"What main barriers reduce the long-term efficacy of CAR T cell therapies?\",\"answer\":\"Key obstacles include insufficient antigen specificity, limited survival and persistence of transplanted T cells in vivo, and an unfavorable tumor microenvironment (TME).\"},{\"question\":\"What hypothesis does the review present to improve CAR T cell outcomes?\",\"answer\":\"It hypothesizes that enhancing donor T cells’ ability to compete with cancer cells for key nutrients can overcome T-cell exhaustion and sustain durable antitumor function in the TME.\"},{\"question\":\"How does nutrient gene therapy using GLUT1 relate to the proposed treatment strategy?\",\"answer\":\"The approach uses genetic overexpression of GLUT1 (glucose transporter 1) to strengthen the metabolic competency of adoptive CAR T cells, deprive tumors of critical metabolites and ATP, and disrupt the TME.\"}]","Nutrient-gene therapy as a strategy to enhance CAR T cell function and overcome barriers in the tumor microenvironment - Review | PDF",1790183449,45,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c9587fa251fff815963e92eae7d65434.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1cf632214829d4264dc465e248ff4cf2.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3d1c2be5074f0347b4d5fa823b55bbc3.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a9763dfe1fca9e590e26b4c9d4a3c1fa.webp",980,1301]